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Abstract
Purpose:  The  aim  of  the  study  was  to  evaluate  the  role  of  anti-VEGF  therapy  as  an  adjunct  to
laser ablation  therapy  in  severe  aggressive  posterior  retinopaty  of  prematurity  (AP-ROP).
Methods:  Medical  records  of  premature  infants  with  a  primary  diagnosis  of  AP-ROP  treated  with
0.625 mg/0.025  ml  intravitreal  bevacizumab  (IVB)  in  addition  to  standard  laser  photocoagulation
as a  salvage  therapy  or  primarily  combined  with  laser  in  a  university  clinic  were  reviewed,
retrospectively.  The  anatomical  results  and  complications  were  evaluated  after  treatment.
Results: 15 eyes  of  9  patients  with  a  mean  gestational  age  of  28.3  weeks  (range,  26--31  w)  and
mean birth  weight  of  1090  g  (range,  860--1330  g)  were  included  in  the  study.  They  all  had  Zone  1
or posterior  Zone  2  plus  disease  staging  between  severe  3  and  4a.  Twelve  eyes  were  treatment
naive at  the  beginning.  The  mean  follow-up  was  19.5  ±  11.8  months  (range,  11--40  months).  The
disease regressed  totally  in  6  eyes  (40%),  stayed  stable  as  stage  4a  in  1  eye  (6.7%),  progressed
to and  stabilized  at  stage  4a  in  3  eyes  (20%)  and  progressed  to  stage  5  in  3  eyes  (20%)  within
7--10 days.  Two  eyes  (13.3%)  developed  hypotony  and  cataract.
Conclusion: The  association  of  IVB  and  laser  ablation  might  decrease  the  progression  rate  in
severe AP-ROP.  Prompt  regression  of  iris  neovascularization  encourages  its  use  in  cases  with
pupillary  rigidity  to  allow  for  laser  treatment.  When  used  as  a  salvage  therapy  it  may  not
change the  overall  result  dramatically.
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Resumen
Objetivo:  El  objetivo  del  estudio  fue  la  evaluación  del  papel  de  la  terapia  anti-VEGF  como
complemento  a  la  terapia  de  ablación  por  láser  en  la  retinopatía  posterior  agresiva  severa  del
prematuro  (AP-ROP).
Métodos:  Se  revisaron  retrospectivamente  los  informes  médicos  de  nin˜os  prematuros  con  diag-
nóstico primario  de  AP-ROP,  tratados  con  0,625  mg/0,025  ml  de  bevacizumab  intravítreo  (IVB),
además de  fotocoagulación  con  láser  estándar  como  terapia  de  rescate,  o  previamente  combi-
nado con  láser,  en  una  clínica  universitaria.  Tras  el  tratamiento  se  evaluaron  los  resultados  y
complicaciones  anatómicas.
Resultados: Se  incluyeron  en  el  estudio  15  ojos  de  9  pacientes  con  una  edad  media  de  gestación
de 28,3  semanas  (rango,  26-31  semanas)  y  un  peso  medio  al  nacer  de  1090g  (rango,  860-1330g).
Todos ellos  tenían  enfermedad  de  zona  1  o  zona  2  plus  posterior,  con  niveles  comprendidos  entre
3 severa  y  4a.  Al  inicio,  doce  ojos  no  habían  sido  tratados  anteriormente.  El  seguimiento  medio
fue de  19,5±11,8  meses  (rango,  11-40  meses).  La  enfermedad  mostró  una  regresión  total  en  6
ojos (40%),  permaneció  estable  en  estadio  4a  en  1  ojo  (6,7%),  progresó  y  se  estabilizó  en  estadio
4a en  3  ojos  (20%)  y  progresó  a  estadio  5  en  3  ojos  (20%),  durante  un  periodo  comprendido  entre
7 y  10  días.  Dos  ojos  (13,3%)  desarrollaron  hipotonía  y  cataratas.
Conclusión: La asociación  de  IVB  y  la  ablación  por  láser  puede  hacer  disminuir  la  tasa  de  pro-
gresión en  la  AP-ROP  severa.  La  rápida  regresión  de  la  neovascularización  del  iris  estimula  su
uso en  casos  con  rigidez  de  la  pupila,  dejando  margen  a  la  terapia  con  láser.  Su  uso  como  terapia
de rescate  puede  no  modiﬁcar  drásticamente  el  resultado  general.
© 2012  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  España,  S.L.  Todos  los
derechos  reservados.
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etinopaty  of  prematurity  (ROP)  is  a  proliferative  disorder
f  the  developing  retina  that  continues  to  be  a  major  cause
f  blindness  of  children  in  the  developed  and  developing
orld.1,2 Both  Cryo-ROP3 and  Early  Treatment  ROP4,5 studies
emonstrated  improved  structural  and  functional  outcomes
ith  peripheral  ablation.  Although  incidence  of  retinopa-
hy  was  similar  in  these  two  studies,  an  increase  in  the
ccurrence  of  Zone  1  ROP  was  noted  in  the  Early  Treat-
ent  ROP  cohort.  The  increase  in  Zone  1  ROP  is  most  likely
ue  to  increased  survival  of  ultrapremature  infants  (gesta-
ional  age  <  26  weeks,  birth  weight  <  750  g,  or  both)  because
f  improved  neonatal  care.
Aggressive  posterior  ROP  (AP-ROP)  is  characterized  by
one  1  or  posterior  Zone  2  ROP  requiring  treatment  per
arly  Treatment  ROP  standards  (any  plus  disease  or  stage
 disease).  These  infants  are  characterized  by  ﬂat  neo-
ascularization  (stage  3),  plus  disease,  or  both  generally
ccurring  by  postmenstrual  age  of  <34  weeks.  Management  is
omplicated  by  a  poor  view  of  the  fundus  because  of  persis-
ent  tunica  vasculosa  lentis  and  persistent  fetal  vasculature.
omplete  laser  ablation  may  not  be  possible  in  a  single
ession,  and  repeat  laser  ablation  may  be  warranted.  The
rognosis  of  AP-ROP  is  still  guarded  even  with  treatment;
he  cryotherapy  for  Retinopathy  of  Prematurity  Coopera-
ive  (Cryo-ROP)  Study  reported  a  77.8%  unfavorable  outcome
ate  with  cryotherapy,  and  the  Early  Treatment  for  Retinopa-
hy  of  Prematurity  Cooperative  Group  (ET-ROP)  reported  a
5.2%  unfavorable  outcome  rate  with  laser  photocoagulation
n  Zone  1  disease.3,4
1
w
a
bIt  is  currently  understood  that  ROP  is  a  biphasic  disease
onsisting  of  an  initial  phase  of  oxygen-induced  vascular
bliteration  followed  by  a  period  of  hypoxia-induced  vessel
roliferation.6 Anti-VEGF  therapy  may  be  effective  in  the
econd  phase  and  as  a  single  dose  because  there  is  theo-
etically  only  1  burst  of  VEGF.7 This  is  in  contrast  to  other
cular  neovascular  conditions,  such  as  age-related  macu-
ar  degeneration  and  diabetic  retinopathy,  where  aberrant
EGF  production  often  recurs  as  a  result  of  longstanding  dis-
ase.  Sonmez  and  associates  reported  a  signiﬁcant  increase
n  the  intravitreal  levels  of  VEGF  in  vascularly  active  stage  4
isease,  indicating  that  the  administration  of  bevacizumab
hould  be  before  the  onset  of  this  increase,  such  as  during
tage  3.8
On  the  basis  of  reports  of  the  successful  use  of  anti-
EGF  agents  in  the  treatment  of  retinal  proliferative
iseases,  several  groups  have  conducted  preliminary  trials
ith  intravitreal  bevacizumab  (IVB)  (Avastin;  Genentech,
an  Francisco,  CA)  in  small  series  of  patients  with  ROP  as
n  adjunct  (to  laser)  or  salvage  therapy  or  as  monother-
py  with  favorable  anatomical  outcome  in  some  of  the
ases.9--30
Currently,  the  results  of  BEAT-ROP  study  (Beva-
izumab  eliminates  the  angiogenic  threat  of  retinopathy
f  prematurity)  which  is  a  randomized  controlled  Phase  II
ulticenter  trial  exploring  the  safety  and  efﬁcacy  of  IVB
or  Stage  3  ROP  in  severe  Zone  I or  posterior  Zone  II  in
50  premature  neonates  have  been  released.  The  babies
ere  randomized  to  receive  conﬂuent  laser  or  IVB  0.625  mg
s  primary  therapy  in  both  eyes.  The  results  showed  that
evacizumab  uniformly  reduced  neovascularization  and
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Table  1  Demographic  data  of  the  babies.
Case  Gestational  age
(weeks)
Birth  weight
(g)
Age  at  treatment
(weeks)
Systemic  problems
Case  1  31  1000  F  Twin,  RDS
Case 2  28  1100  M  RDS
Case 3  28  1100  F  Blood  transfusion,  RDS
Case 4  31  1330  F  Sepsis,  RDS,  IVH,  Twin
Case 5  29  1250  F  RDS
Case 6  26  860  M  RDS
Case 7  26  900  F  Sepsis,  RDS
Case 8 28 1100 M Sepsis,  RDS
Case 9 28 1180 M IVH
RDS, respiratory distress syndrome; IVH, intraventricular hemorrhage; M, male; F, female.
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(plus  disease  within  48  h.  Both  persistence/recurrence  of
vascular  activity  and  progression  to  RD  were  signiﬁcantly
lower  in  the  study  group  than  in  the  laser-treated  (control)
group,  especially  in  eyes  with  Zone  I  disease.25 After
encouraging  results  of  BEAT  ROP  study,  in  the  present
study,  we  have  investigated  the  efﬁcacy  of  intravitreal
bevacizumab  (IVB)  treatment  combined  with  laser  ablation
or  as  a  salvage  therapy  after  laser  ablation  in  AP-ROP.
Patients and methods
Medical  records  of  premature  infants  with  a  primary  diag-
nosis  of  AP-ROP  treated  with  intravitreal  bevacizumab
(IVB)  in  addition  to  standard  laser  photocoagulation  as  a
salvage  therapy  or  primarily  in  a  university  clinic  were
reviewed  retrospectively.  All  of  the  surgical  procedures
had  been  performed  by  two  surgeons  (SO,  GG),  including
IVB  injections  and  laser  applications  after  getting  a  con-
sent  form  from  the  parents  explaining  the  off-label  use  of
bevacizumab  and  the  potential  risks  of  the  drug  and  the
injection.
Surgical  technique
Eyes  received  a  near  conﬂuent  pattern  of  indirect  diode
laser  photocoagulation  to  the  avascular  retina,  immediately
anterior  to  the  border  of  the  vascular  zone  extending  to  the
ora  serrata  for  360◦ under  general  anesthesia.
Bevacizumab  (0.625  mg/0.025  ml)  was  injected  intrav-
itreally  using  a  30-gauge  needle  placed  1  mm  behind  the
limbus,  immediately  after  completion  of  photocoagulation
or  later  as  salvage  therapy  in  those  not  responding  to  laser
photocoagulation.
The  data  included  the  demographic  features  of  the
babies,  associated  systemic  problems,  general  health
conditions  of  the  babies  as  well  as  pre  and  postoperative
ophthalmologic  features;  pupillary  dilation,  iris  neovascu-
larization  state,  location  (zone),  extent  (clock  hours)  and
stage  of  the  disease  and  presence  of  plus  disease  or  vitreous
hemorrhage.  Treatment  details  including  the  type  and
amount  of  anti-VEGF  used  and  the  number  of  laser  burns
were  noted.  Patients  were  followed  weekly  during  the  1st
g
a
l
honth  and  monthly  thereafter  if  not  requested  otherwise.
uring  the  follow-up  period,  all  of  the  above  data  were
eviewed  to  determine  the  postoperative  complication  and
natomical  success  rate.
esults
ifteen  eyes  of  9  consecutive  patients  (6  boys,  3  girls)
ere  included  in  the  study.  Mean  gestational  age  was
8.3  weeks  (range,  26--31  weeks),  mean  birth  weight  was
090  g  (range,  860--1330  g)  and  mean  follow  up  time  was
9.5  ±  11.8  months  (range,  11--40  months).  Seven  of  9
nfants  had  severe  systemic  problems  (8  had  respiratory
istress  syndrome,  2  had  intraventricular  hemorrhage  and
 had  sepsis)  at  postpartum  period.  Demographic  data
re  listed  in  Table  1.  They  were  all  referred  from  other
ospitals  to  our  center  for  ROP  treatment.
All  eyes  were  Zone  1  (13  eyes)  or  posterior  Zone  2  (2
yes).  All  eyes  had  plus  disease  before  treatment  (Table  2).
hey  were  all  severe  stage  3  or  4a  eyes  and  12  eyes  were
reatment  naive  at  the  beginning  and  two  patients  were  sent
rom  other  hospitals  to  our  center  after  inadequate  laser
reatment.  Mean  number  of  laser  spots  applied  in  our  clinic
as  2136  ±  585  spots  (range,  1900--3000).  Two  eyes  (13%)
eceived  IVB  injection  at  the  same  session  with  laser  photo-
oagulation  because  of  the  presence  of  severe  plus  disease,
nd  13  eyes  (87%)  received  IVB  later  as  a  salvage  therapy.
All  of  the  eyes  had  a  signiﬁcant  decrease  in  plus  dis-
ase  as  observed  by  ﬁrst  clinical  examination  in  the  1st
eek.  Eight  eyes  of  4  infants  (cases  1,  6,  8  and  9)
ad  pupillary  problems  (anterior  neovascularization  and
oor  dilation)  before  treatment,  and  developed  beneﬁcial
esponse  to  treatment  with  decreased  engorged  iris  ves-
els  permitting  dilation  of  the  pupils.  The  disease  regressed
otally  in  6  eyes  (40%),  stayed  stable  as  stage  4a  in
 eye  (6.7%),  progressed  to  and  stabilized  at  stage  4a
n  3  eyes  (20%)  and  progressed  to  stage  5  in  5  eyes
33.3%)  within  7--10  days.  Two  of  the  3  eyes  with  pro-
ression  to  stage  5  (case  1  and  6)  developed  hypotony
nd  cataract.  Macula  was  on  in  66.6%  of  the  eyes  at  the
ast  control  visits.  Of  the  4  eyes  having  mild  vitreous
emorrhage  before  treatment,  only  one  regressed  after
54  S.  Ozdek  et  al.
Table  2  Clinical  Characteristics  of  Patients.
Case/eye  Zone  Stage  Plus  disease
pre/post-treat.
Pupil  problem  (RI  or
poor  dilatation)
pre/post-treat.
Vitreous
hemorrhage
pre/post-treat.
Follow-up
(months)
Prognosis
Case  1
R  Zone  1  3  +/−  +/  −/+  14  Anterior  segment  ischemia
L Zone  1  3  +/−  +/  −/+  Progression  (stage  5)b
Case  2  P.Zone  2  3  +/−  −/−  −/−  12  Progression  (stage  4a)
Case 3  Zone  1  4a  +/−  −/−  −/−  14  Stabile  (stage  4a)
Case 4
R Zone  1 4a +/− −/−  +/+  40  Progression  (stage  5)b
L Zone  1 4a +/− −/−  −/−  Regression
Case 5 P.Zone  2  4a  +/−  −/−  −/−  39  Regression
Case 6a
R  Zone  1  3  +/−  +/−  +/+  11  Anterior  segment  ischemia
L Zone  1  3  +/−  +/−  −/−  Regression
Case 7
R Zone  1 3  +/−  −/−  −/+  23  Progression  (stage  5)b
L Zone  1 3 +/−  −/−  +/−  Regression
Case 8
R  Zone  1  3  +/−  +/−  −/−  12  Regression
L Zone  1  3  +/−  +/−  −/−  Progression  (stage  4a)
Case 9
R  Zone  1  3  +/−  +/−  +/−  11  Progression  (stage  4a)
L Zone  1  3  +/−  +/−  −/−  Regression
a IVB injection at the same session with laser photocoagulation.
b Pars plicata vitrectomy + lensectomy performed.
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areatment  (case  7/L)  and  other  three  eyes  progressed  to
tage  4a  or  5  (Table  2).  New  vitreous  hemorrhage  devel-
ped  in  another  3  eyes  following  treatment  all  of  which
rogressed  to  stage  5.
No  alteration  in  blood  pressure  or  systemic  condition
as  observed  suggesting  the  absence  of  systemic  toxicity
f  the  bevacizumab  in  any  of  the  patients  following  treat-
ent.
iscussion
P-ROP  is  an  uncommon  disease  and  comprises  10%  of
OP  requiring  treatment.  It  is  well  established  that  Zone
 disease  often  progresses  despite  conventional  therapies;
nfavorable  outcomes  up  to  55--78%  such  as  macular  fold  and
ragging,  retrolental  mass  and  retinal  detachment  could  be
bserved  in  APROP  eyes  as  proven  by  prospective  controlled
tudies.26 The  disappointing  results  in  APROP  stimulated
any  authors  to  ﬁnd  better  treatment  modalities  for  these
yes.  The  use  of  bevacizumab  in  ROP  has  become  a  rela-
ively  new  topic  in  retinal  research  and  the  question  still
emains  in  the  adequacy  of  the  use  of  bevacizumab  for  the
reatment  of  ROP.
Currently,  one  of  the  two  randomized  controlled  studies
xploring  the  safety  and  efﬁcacy  of  IVB  for  ROP  is  named
s  ‘‘Pan-VEGF  blockade  for  the  treatment  of  retinopathy
t
l
a
lf  prematurity  (BLOCK-ROP),  clinical  trials  identiﬁer
CT00702819’’  which  is  a  Phase  I  multicenter  study  of  the
afety  and  efﬁcacy  of  unilateral  IVB  in  premature  neonates
ith  posterior  ROP  that  is  unresponsive  to  laser  treatment.
owever,  this  phase  of  BLOCK-ROP  was  terminated  due  to
nsufﬁcient  enrollment----ROP progression  with  timely  and
ffective  laser  for  APROP  was  rare  at  BLOCK-ROP  study
enters.  Two  infants  were  enrolled  over  the  course  of  a
ear  (unpublished  data).31 A  second  phase  of  the  BLOCK-
OP  study  (NCT01232777)  targets  all  treatment-eligible
nfants  (Type-1  threshold  ROP),  with  an  internal  control
or  more  rigorous  comparison  of  treatment  efﬁcacy.  This
ose-ranging  Phase  II  study  will  aim  to  demonstrate  non-
nferiority  of  IVB  compared  with  standard-of-care  laser.  In
his  randomized  three-armed  trial,  one  group  of  infants
ill  receive  0.75  mg  IVB  in  one  eye  and  laser  treatment
n  the  fellow  eye;  a  second  group  will  receive  a  lower
ose  of  0.625  mg  IVB  in  one  eye  and  laser  treatment  in
he  fellow  eye;  and  a third  group  of  infants  will  receive
aser  photocoagulation  in  both  eyes.  It  is  hoped  that,  by
his  study  design,  the  relative  risk  of  increased  myopia,
mblyopia  and  functional  outcomes  can  be  assessed,  since
he  eye  treated  with  IVB  can  be  compared  with  the  fel-
ow  laser-treated  eye  of  the  same  infant.  Additionally,
 lower  effective  dose  of  bevacizumab  may  be  estab-
ished.
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The  second  study,  ‘‘Bevacizumab  eliminates  the  angio-
genic  threat  of  retinopathy  of  prematurity  (BEAT-ROP),’’  is
a  Phase  II  multicenter  trial  in  which  150  premature  neonates
with  severe  stage  3  ROP  in  Zone  I  or  posterior  Zone  II
were  randomized  to  receive  conﬂuent  laser  or  IVB  0.625  mg
as  primary  therapy  in  both  eyes.  The  results  showed  that
out  of  143  infants  who  survived  to  week  54  postmenstrual
age,  ROP  recurred  in  4%  of  the  bevacizumab  group  and
22%  of  the  laser  group.25 Both  persistence/recurrence  of
vascular  activity  and  progression  to  RD  were  signiﬁcantly
lower  in  the  study  group  than  in  the  laser-treated  (con-
trol)  group,  especially  in  eyes  with  Zone  I  disease.  Still
there  is  a  considerable  concern  regarding  the  choice  of  anti-
VEGF,  its  dosage,  timing  of  injections,  the  possible  need
for  multiple  injections,  the  reality  that  local  complications
of  ocular  trauma  or  endophthalmitis  may  occur,  and,  most
importantly,  the  possibility  that  both  acute  and  long-term
systemic  complications  may  be  caused  by  anti-VEGF  therapy
since  the  BEAT-ROP  study  was  not  powered  to  assess  safety.
Shah  et  al.  described  visual  acuity  and  electroretinogra-
phy  ﬁndings  3½ years  after  the  ﬁrst  IVB  injection  in  a
case  of  APROP.  They  suggested  that  IVB  did  not  have  an
adverse  effect  on  the  ERG  but  could  have  on  the  ﬁnal  visual
acuity.32
An  important  advantage  of  IVB  therapy  is  the  continua-
tion  of  peripheral  retinal  vascularization  after  treatment.
Hoang  et  al.  evaluated  ﬂuorescein  angiography  of  recur-
rent  ROP  after  initial  IVB  treatment.  After  2  months  of
IVB  injection  they  documented  circumferential  anastomo-
sis  at  the  bevacizumab  induced  regression  site  with  radial
vessels  progressing  anteriorly  to  form  a  second  stage  3
complex.  This  case  also  provided  further  support  that
IVB  did  not  necessarily  inhibit  subsequent  retinal  vascular
development.33
There  are  several  articles  reporting  the  use  of  IVB  for
treatment  of  Zone  1  and  posterior  Zone  2  diseases,  as
monotherapy  or  in  combination  with  conventional  laser
therapy  or  vitrectomy9--30 (Tables  3  and  4).  There  are  109
eyes  of  63  patients  treated  with  IVB  in  conjunction  to
lasers  all  of  which  had  APROP  (Table  3).  Each  report  was
of  a  different  design  and  used  a  different  dose  of  beva-
cizumab,  the  most  commonly  used  dose  being  0.625  mg.
Of  the  109  eyes  in  the  studies,  41  (38%)  eyes  received
IVB  as  an  adjunct  to  laser  photocoagulation  initially,  35
(32%)  eyes  received  IVB  as  a  salvage  therapy  for  severe
laser-refractory  ROP  and  33  (30%)  eyes  received  IVB  for  the
limited  visibility  of  the  fundus  because  of  vitreous  haze  or
hemorrhage  and  other  media  opacities  and  poor  pupillary
dilatation  or  in  infants  who  are  too  unstable  medically  to
safely  undergo  the  prolonged  general  anesthesia.  In  101
(93%)  eyes  plus  disease  disappeared  completely  and  ROP
regressed  without  complication  and  the  anatomical  results
were  favorable.  Seven  (6%)  eyes  experienced  a  progression
to  tractional  RD  with  whitening  and  contraction  of  the  neo-
vascular  membranes  and  one  eye  (1%)  developed  macular
fold.
The  use  of  IVB  as  monotherapy  for  ROP  treatment  has
been  reported  in  a  total  of  263  eyes  of  136  patients  from
several  studies,  of  which  almost  all  had  APROP  (Table  4),
and  the  most  commonly  used  dose  was  again  0.625  mg.  In
257  (97%)  eyes,  plus  disease  disappeared  completely  and
ROP  regressed  without  complication  and  the  anatomical
u
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esults  were  favorable.  Six  eyes  needed  laser  therapy  1.5
onth  after  IVB  injection  in  spite  of  the  initial  treatment
esponse.  Four  (1.5%)  eyes  experienced  vitreous  and  pre-
etinal  hemorrhage,  3  (1%)  eyes  experienced  a  progression
o  tractional  RD  and  one  eye  (0.37%)  developed  macular
ragging.
The  outcome  of  our  series  of  AP-ROP  cases  treated  with
VB  combined  with  conventional  laser  therapy  is  not  par-
llel  to  the  results  presented  in  the  literature.  Although
he  effects  of  bevacizumab  to  halt  the  plus  disease  and
nterior  neovascularization  were  remarkable,  it  does  not
eem  to  change  the  unfavorable  outcomes  and  progres-
ion  of  the  severe  ROP  when  used  in  association  with  laser
hotocoagulation  or  as  a  salvage  therapy  in  our  cases.  All
f  the  eyes  in  our  series  had  Zone  1  or  posterior  Zone
 disease  with  severe  stage  3  and  stage  4a;  therefore
he  prognosis  was  poor  and  the  disease  regressed  totally
nly  in  40%  of  eyes.  However  it  is  difﬁcult  to  make  any
onclusion  with  this  information  since  the  timing  of  ther-
py  and  case  selection  is  still  a  problem  in  APROP  cases.
ur  impression  is  that,  the  severity  of  stage  3  disease
lays  an  important  role  in  response  to  IVB  therapy.  When
t  is  a  severe  stage  3  disease  where  extraretinal  dilated
bnormal  vessels  in  ridge  are  highly  elevated  through  vit-
eous,  IVB  therapy  leads  to  conversion  of  these  vessels  to
 ﬁbrotic  tissue  causing  traction  of  the  retina.  However
hen  it  is  a  mild  stage  3  disease  in  Zone  1  with  a  ﬂat
eovascularization,  those  eyes  respond  well  to  IVB  ther-
py.
Another  cause  of  poor  outcome  of  the  IVB  therapy  in
ur  series  is  its  use  as  a  salvage  therapy  which  occurred
n  most  (83%)  of  the  eyes.  Which  means  that,  IVB  was  given
o  those  eyes  that  did  not  respond  well  to  the  laser  treat-
ent  and  had  tendency  to  progress  to  stage  4.  The  high
ate  of  anterior  segment  ischemia  (15.3%)  in  our  cases  added
o  the  poor  outcome.  This  is  possibly  because  of  the  need
or  huge  amount  of  laser  photocoagulation  in  very  large
vascular  areas  in  Zone  1  disease.  The  mean  number  of
urns  in  our  cases  that  developed  anterior  segment  ischemia
as  2452  ±  311  spots.  Anterior  segment  ischemia  has  been
eported  by  Fallaha  and  associates,  where  a  2.3%  rate  of
nterior  segment  ischemia  was  seen  in  their  cohort  of  91
yes.35 Kaiser  and  Trese  reported  on  8  eyes  of  5  patients
eferred  from  other  clinics  who  developed  cataracts,  iris
trophy  and  hypotony,  all  symptoms  indicative  of  anterior
egment  ischemia  following  laser  photoablation.36 Lambert
t  al.  reported  a  series  of  10  eyes  that  developed  cataracts
nd  phthisis  bulbi  secondary  to  anterior  segment  ischemia
ollowing  laser  photoablation  for  threshold  ROP  where  the
ean  number  of  burns  applied  was  2532  ±  856  similar  to  our
ases.37
In  conclusion,  despite  the  limitations  of  this  study  (its
etrospective  nature,  absence  of  a  control  group  and  a
mall  number  of  patients  and  limited  functional  results)  the
ddition  of  IVB  after  the  laser  ablation  slightly  decreased
he  progression  rate  in  severe  AP-ROP  eyes.  Prompt  regres-
ion  of  iris  neovascularization  encourages  its  use  in  cases
ith  pupillary  rigidity  to  allow  for  laser  treatment.  When
sed  as  a  salvage  therapy  it  may  not  change  the  over-
ll  result  dramatically.  Limited  literature  on  this  subject
ndicates  that  prospective  randomized  controlled  trials  are
arranted.
56
 
S.
 O
zdek
 et
 al.
Table  3  Characteristics  of  the  cases  in  the  literature  reporting  the  use  of  IVB  as  an  adjunct  to  laser  photocoagulation  or  salvage  for  the  treatment  of  ROP.
References  No.  of  patients
(eyes)  treated
with  IVB
Mean
gestational
age  (weeks)
Mean  birth
weight  (g)
State  before  IVB  Treatment  used  in
conjunction  with
bevacizumab
Dose  of  IVB
used  (mg)
Outcome  with
IVB
Chung  and  associates,
200711
1  (2)  25  884  Zone  I,  stage  3+  LP  0.75  Regression  of
ROP  (100%)
APROP Combined  treatment
Shah and
associates,  200710
1  (1)  31  1170  APROP  Previous  LP  0.75  Regression  ROP
Iris rubeosis  Salvage  therapy
Honda and  associates,
200815
1  (1)  23  598  Stage  4A  Previous  LP
Salvage  therapy
0.40  Funnel  TRD
Lalwani and  associates,
200812
3  (5)  24  721.6  Threshold  ROP  Previous  LP  0.625  Regression  of
ROP  (80%)
Reactivation  of  NV  Salvage  therapy  RRD  (20%)
Zone I,  plus  disease  LP  supplementation
Bilateral  RD
Law and
associates,  201017
7 (13)  25 700 Iris  rubeosis,  dense  vitreous  LP  Regression  of
ROP  (69%)
hemorrhage,  increasing 8  eyes  combined  treatment  0.75  TRD  (23%)
vascular activity  and  vitreoretinal
traction
5  eyes  salvage  therapy  TRD-RRD  (8%)
Lee and
associates,  201019
8  (16)  25.7  820.6  Zone  I/Posterior  Zone  II  LP  0.50  Regression  of
ROP  (100%)
Stage 3+  Combined  treatment
Erol and
associates,  201029
4  (7)  ?  ?  Zone  I/Posterior  Zone  II  Previous  LP  Regression  of
ROP  (86%)
Stage 3+  Salvage  therapy
Nazari and  associates,
201023
8  (14)  27.6  1047 Severe  ROP  associated  with  vitreous
or retinal  hemorrhage  plus  disease
Previous  LP  0.625  Regression  of
ROP  (100%)
Salvage  therapy
Wutthiworawong  and
associates,  201126
12  (23)  ?  ?  APROP  LP  ?  Regression  of
ROP  (100%)
Combined  treatment
Axer-Siegel and  associates,
201127
4  (8)  24--27  660--1131  Zone  I/Posterior  Zone  II  Previous  LP  0.75  Macular  fold  1
eye  (12.5%)
Stage 2,  3,  4a  plus  disease  Salvage  therapy
Roohipoor and  associates,
201128
8  (8)  28.5  1218  Zone  II  stage  3  Previous  LP  0.625  Regression  of
ROP  (100%)
Hyphema (3),  vitreus  hemorrhage  (1),
persistent  disease  activity  (4)
Salvage  therapy
IVB, intravitreal bevacizumab; TRD, tractional retinal detachment; RRD, regmatogenous retinal detachment; LP, laser photocoagulation.
Intravitreal
 anti-VEG
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Table  4  Characteristics  of  the  cases  in  the  literature  reporting  the  use  of  intravitreal  Bevacizumab  monotherapy  for  the  treatment  of  ROP.
References No.  of  patients
(eyes)  treated
with  IVB
Mean
gestational  age
(weeks)
Mean  birth
weight  (g)
State  before  IVB Treatment  used  in
conjunction  with
bevacizumab
Dose  of  IVB
used  (mg)
Outcome  with  IVB
Travassos  and
associates,  20079
3  (3) 24.3 603 Anterior  NV
posterior  Zone  II
(2)
No 0.75  Regression  of  ROP
Anterior NV  after
laser  for  Zone  I  (1)
Yes  (1  eye  salvage) 0.75  Regression  of  ROP
Kong and
associates,  2008
1  (2) 22 350 Zone  I,  stage  2+ No 0.50  Regression  of  ROP
Zone II,  stage  3+ No 0.50  Regression  of  ROP
Quiroz-Mercado and
associates,  200813
13  (18) 29.1 1233 Stage  4A,  4B,  3+
Eyes  unable  to  be
graded
No
Yes  (4  eyes
salvage)
1.25  Regression  of  ROP  (94%)
TRD  (6%)
Mintz-Hittner and
associates,  200814
11  (22) 24.3 706 Zone  I/Post-Zone  II No 0.625  Regression  of  ROP  (100%)
AP-ROP
Dorta and
associates,  201020
7  (12) 25.5 846  Zone  I/Zone  II  No  0.625  Regression  of  ROP  (100%)
APROP
Mintz-Hittner and
associates,  201125
(BEAT-ROP  study)
70  (140)  24.2  615  Zone  I  stage  3+  No  0.625  Regression  of  ROP  (94%)
24.5 689  Post-Zone  II  stage
3+
No  0.625  Regression  of  ROP  (95%)
Axer-Siegel and  associates,
201127
5  (10)  (24--26)  620
--825
APROP  No  0.75  Regression  of  ROP  (100%)
Roohipoor and  associates,
201128
2  (4) 28.5 1218  APROP  No  0.625  Regression  of  ROP  (100%)
2 eyes  needed  adjuvant  laser
therapy
Harder and  associates,
201130
12  (23) 25.1 625 Threshold  ROP
Zone  I/Zone  II
APROP
No 0.375  Regression  of  ROP  (100%)
Wu and  associates,
201124
23  (41) 25.7 845 Zone  1/Zone  II  No  0.625  Regression  of  ROP  (90%)
Stage 3+ Yes  (5  eyes
salvage)
4  eyes  needed  adjuvant  laser
treatment
Vitreus  and  preretinal
hemorrhage  (10%)
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